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Abstract
Increasing antimicrobial resistance in strains of Escherichia coli is having a major impact on 
the healthcare industry worldwide. The appearance of extended-spectrum β-lactamase 
(ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) strains has caused clinicians 
to worry that these strains might become as deadly as methicillin-resistant Staphylococcus 
aureus (MRSA) strains. It is vital that physicians have resources available to help keep 
them updated on these bacteria and the potential impact on healthcare. This chapter 
reviews the major strains of E. coli (intestinal and urinary), along with a review of the 
virulence factors, main diseases caused, and pertinent pathogenesis. The chapter then 
discusses antimicrobial therapy, what drugs are effective against these E. coli strains, and 
the development of resistance to these specific drug classes. Lastly, the molecular aspects 
of antimicrobial resistance mechanisms in this organism are discussed. This information 
will be especially helpful for physicians in providing them with a concise review of E. 
coli and an understanding of what is involved in antimicrobial resistance. Hopefully this 
information can be used to improve the outcomes for patients with E. coli infections.
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1. Introduction
Increasing resistance to antimicrobial drugs is of major concern worldwide. For many devel-
oping countries, the possibility of having cheap antibiotics available may now be threatened. 
There are antimicrobial resistance issues with most pathogenic bacteria and in virtually all of 
the opportunistic bacterial-caused infections. This translates into increased healthcare costs. 
These costs include extended length of hospital stay and increased costs for medical sup-
plies including more expensive antimicrobial drugs. In addition, antimicrobial drug-resistant 
infections lead to higher rates of mortality, especially in patients who had recent prior expo-
sure to antibiotics [1].
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Antimicrobial drugs are classified into groups according to the type of antimicrobial activity. 
These groups include drugs that inhibit bacterial cell wall synthesis, depolarize the cell mem-
brane, inhibit bacterial protein synthesis, inhibit bacterial nucleic acid synthesis, and inhibit 
bacterial metabolic pathways. The improper use of these drugs has helped to create resistant 
bacterial strains. Factors that contribute to resistance include the increased use of all antimi-
crobial drugs and improper antimicrobial prescribing. Many of the less expensive drugs that 
have fewer side effects have been used too commonly. Improper prescribing may be choosing 
broad spectrum or ineffective drugs [2–4].
Many strains of Escherichia coli are not harmful. In fact, these commensal strains in the gut are 
necessary for the synthesis of vitamin K
2
, which is an important clotting factor [5]. However, 
there are pathogenic strains, and these strains may become a larger threat if they possess or 
acquire certain antimicrobial mechanisms. The main ones of concern are the extended-spec-
trum β-lactamase (ESBL)-producing strains and the carbapenem-resistant Enterobacteriaceae 
(CRE) strains. The ESBL strains are resistant to most β-lactam drugs, and the CRE strains are 
resistant to most carbapenem drugs. Greatly increased healthcare costs are associated with 
the ESBL and CRE strains. Various studies have shown a hospital stay of up to twice as long 
and increased costs of 1.5–2.5 times as much [6–8]. One study in the United States estimated 
the increased costs to be $16,450 per patient [6].
All of the pathogenic strains of E. coli are armed with the same types of potential virulence fac-
tors. These factors include a capsule (in some strains), flagella, the lipopolysaccharide (LPS) 
cell wall, fimbriae, outer membrane proteins (OMPs), a hemolysin, cytolysins, and sidero-
phores. The specific types of some of these virulence factors plus the possession of other tox-
ins and effectors may vary with each individual pathogenic strain [9].
2. Pathogenic strains of Escherichia coli
Commensal strains of E. coli are the predominant facultative organism in the human gut. 
Even though greatly outnumbered by the anaerobic organisms, the E. coli are vital to human 
health, playing roles in biofilm communities and subsequent digestion of oligosaccharides 
and polysaccharides, among other things [10, 11]. Unfortunately, there are also several patho-
genic strains of E. coli. The classification names of these strains may vary some depending on 
the source, but for the purposes of this chapter, we will use the following names. There are six 
strains of potentially pathogenic intestinal-based diarrhea causing E. coli: diffusely adherent 
E. coli (DAEC), enteroaggregative E. coli (EAEC), enterohemorrhagic E. coli (EHEC), entero-
invasive E. coli (EIEC), enteropathogenic E. coli (EPEC), and enterotoxigenic E. coli (ETEC). In 
addition, there is one extraintestinal pathogenic strain, uropathogenic E. coli (UPEC), which 
causes urinary tract infections. There is some evidence that a second extraintestinal strain 
exists, the meningitis-associated E. coli (MNEC) strain. Findings on MNEC indicate that the 
infection starts as a blood infection and then gains access to the central nervous system. A 
majority of MNEC possess the K1 capsular antigen, and there is a high rate of mortality from 
the meningitis [12]. This chapter will focus on the six intestinal and the UPEC strains.
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2.1. Diffusely adherent Escherichia coli (DAEC)
These strains are sometimes referred to as enteroadherent E. coli (EAEC) (not to be confused 
with the enteroaggregative strains, which are sometimes referred to as EAggEC). While not 
known to cause severe diarrheal disease, the DAEC, which are probably a group of related 
strains, are thought to be responsible for some types of persistent diarrhea in infants. Whether 
they possess true virulence factors is still under debate, but these bacteria are able to bind to 
enterocytes (probably via adhesins such as Afa/Dr) and elicit a response in which the micro-
villi extend and wrap around the bacteria. Diarrhea in association with DAEC has also shown 
an ability to induce the production of inflammatory cytokines, such as IL-8 [13–15].
2.2. Enteroaggregative Escherichia coli (EAEC)
The EAEC strains were so named because of their tendency to adhere to enterocytes in dense 
clusters. The bacteria attach to the microvilli and also to other EAEC bacteria. The EAEC are 
also a heterogeneous group of strains with a similar pathogenesis, resulting in non-bloody 
diarrhea. Infection is established by adhering to the microvilli via fimbriae (the aggregative 
adherence fimbriae—AAF), inducing increased mucus production and biofilm formation, 
inducing an inflammatory response and production of toxins. The main toxins of the EAEC 
strains are the EAEC heat-stable enterotoxin (EAST1), which enters the enterocytes and acti-
vates guanine cyclase, resulting in increased levels of cGMP in the cell and loss of fluid into 
the intestinal lumen; the plasmid-encoded toxin (Pet), which disrupts the enterocyte cytoskel-
eton, resulting in cell detachment; and a Shigella-like enterotoxin (ShET1), a heat-stable toxin 
which may also result in fluid secretion [16–18].
2.3. Enterohemorrhagic Escherichia coli (EHEC)
The most publicized strain of pathogenic E. coli is the EHEC strain. EHEC serotype O157:H7 
is well known as the causative agent of outbreaks of food-associated severe diarrhea. Infection 
with O157:H7 results in sever abdominal cramps and bloody diarrhea and may lead to hemo-
lytic-uremic syndrome (HUS) which can be life-threatening. The most common foods asso-
ciated with transmission of these bacteria are undercooked meat (especially ground beef), 
raw milk, and raw vegetables. The EHEC strains do not directly invade the enterocytes, but 
produce toxins that do enter and severely damage these cells. The responsible cytotoxins are 
verotoxins I and II (designated as Shiga toxins, Stx-1 and Stx-2). The Shiga toxins are capable 
of inactivating ribosomes, blocking protein synthesis, and emerging through the basolateral 
membrane into the subepithelial region. Stx-2 is seen most often in the EHEC strains that 
cause HUS [19–21].
2.4. Enteroinvasive Escherichia coli (EIEC)
In infections with EIEC, the bacteria invade by directly entering M cells. The bacteria 
pass through these cells and then are able to invade the enterocytes via the basolateral 
membrane, causing severe damage to the intestinal mucosa. The bacteria are also able 
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to spread laterally through the cell side walls to adjacent cells (via actin). This damage 
results in dysentery (watery diarrhea with pus, mucus, and blood). The EIEC bacteria 
do not produce toxins, but participate in direct damage and induce production of IL-1 
and IL-8. The pathogenic mechanisms and disease symptoms associated with EIEC are 
so similar to Shigella spp. that differential diagnosis can be difficult. Diagnosis is usually 
based on physiological and biochemical characteristics that can be detected in the clinical 
laboratory [19, 22, 23].
2.5. Enteropathogenic Escherichia coli (EPEC)
The EPEC strains do not directly invade enterocytes. Instead, these bacteria adhere to the 
microvilli and inject effector proteins into the cell via a type III secretion system (T3SS). 
One of these effectors is the translocated intimin receptor (Tir), which initiates recruit-
ment of the host cell actin to form a pedestal under the bacteria. The recruitment of actin 
and formation of the pedestals result in destruction of the rest of the microvilli and also 
inhibit the transport of Na+ and Cl- in the cell, which results in the subsequent exodus 
of water into the intestinal lumen. Another effector, the E. coli secreted proteins (Esps), 
interacts with the host cell cytoskeleton and results in disruption of the cell tight junctions 
[24–26].
2.6. Enterotoxigenic Escherichia coli (ETEC)
The ETEC strains are a common cause of acute travelers’ diarrhea. These strains usually colo-
nize the proximal small intestine, adhering to the microvilli via various colonization factors 
including fimbrial, nonfimbrial, helical, and fibrillar types. The EPEC strains secrete two types 
of toxin: a heat-labile toxin (LT) and heat-stable toxins (STs). The LT is an AB toxin, and the B 
subunits bind to the monosialoganglioside GM1, which induces the cell to take in the toxin. 
The LT toxin activates adenylyl cyclase, which increases the cAMP in the cell, resulting in 
hypersecretion of water and electrolytes into the intestinal lumen. The STs bind to guanylyl 
cyclase receptors on the microvilli, which stimulate guanylate cyclase and activate the cystic 
fibrosis transmembrane receptor (CFTR). This results in an increase in cGMP in the cell and 
impaired absorption of Na+, which causes hypersecretion of water into the intestinal lumen 
[19, 24, 27].
2.7. Uropathogenic Escherichia coli (UPEC)
The UPEC strains are responsible for most uncomplicated urinary tract infections (UTIs). These 
strains possess a capsule and bind to uroepithelial cells via fimbriae. The interaction of the bac-
teria with the host cell induces the internalization of the bacteria where the bacteria multiply 
rapidly and form biofilm-like intercellular bacterial communities (IBCs). The bacteria are shed 
intermittently from the uroendothelial cells into the lumen of the bladder. UPEC strains produce 
several types of toxins including hemolysin A (HlyA) which has pore-forming capability and 
two cytotoxins, cytotoxic necrotizing factor (CNF-1) and secreted auto-transporter toxin (Sat) 
[19, 28, 29].
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3. Antimicrobial therapy
As mentioned above, antimicrobial drugs are often classified in groups based on their mechanism 
of antimicrobial action. Table 1 displays those groups along with examples of the antimicrobial 
drugs included in each group. The β-lactam drugs, which were among the first antimicrobials 
to be discovered, target the bacterial cell wall (via peptidoglycan synthesis) and are most use-
ful against gram-positive bacteria (having little effect on gram-negative bacteria because of the 
lipopolysaccharide cell envelope that protects the thin peptidoglycan cell wall in these bacteria). 
Over the years, because the β-lactam drugs were readily available and inexpensive and caused 
few side effects, physicians commonly treated their patients initially with these drugs.
When bacterial resistance to the β-lactam drugs became an issue (very early on), scientists 
developed synthetic versions of penicillin such as ampicillin, amoxicillin, and methicillin. In 
addition, scientists discovered the natural cephalosporin β-lactam drugs. The initial cepha-
losporins (first generation) were most useful against gram-positive cocci, with some activity 
against a few gram-negative bacilli. Further development of these drugs has produced second 
generation (less effective against gram-positive cocci, more effective against gram-negative 
bacilli); third generation (generally with a broad spectrum of activity against gram-negative 
organisms); fourth generation (extended-spectrum activity against gram-positive cocci and 
gram-negative bacilli); and recently, fifth generation (hopefully effective against various 
 
Inhibit cell wall synthesis β-Lactams
Carbapenems
Cephalosporins
Monobactams
Penicillins
Glycopeptides
Depolarize cell membrane Lipopeptides
Inhibit protein synthesis Bind to 30S ribosomal subunit
Aminoglycosides
Tetracyclines
Bind to 50S ribosomal subunit
Chloramphenicol
Lincosamides
Macrolides
Oxazolidinones
Streptogramins
Inhibit nucleic acid synthesis Quinolones
Fluoroquinolones
Inhibit metabolic pathways Sulfonamides
Trimethoprim
Table 1. Antimicrobial groups based on mechanism of action.
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 multidrug-resistant organisms), with more still in development. Other β-lactam drugs devel-
oped during this time frame were the carbapenems (broad-spectrum activity) and monopen-
ems (aztreonam—activity against gram-negative aerobic bacteria) [30–32].
Differences in structure, metabolism, virulence factors, etc., between gram-negative and 
gram-positive bacteria predict which antimicrobial drug groups may be effective. Fewer of 
the drug groups have good activity against gram-negative bacteria. Those groups include 
some of the β-lactam drugs (especially second-, third-, and fourth-generation cephalospo-
rins): aminoglycosides, fluoroquinolones, trimethoprim/sulfamethoxazole (TMP/SXT), and 
nitrofurans (for UTIs) [33]. Intestinal infections with E. coli are most commonly self-limit-
ing and require supportive therapy (antiemetics, antidiarrhetics, rehydration) only. Severe 
or recurring infections (e.g., traveler’s diarrhea) may be treated with fluoroquinolone drugs. 
Acute dysentery caused by EIEC strains may be treated with fluoroquinolones or appropriate 
cephalosporins. For infections caused by EHEC, antimicrobial therapy is contraindicated as it 
greatly increases the risk for development of HUS. UTIs caused by UPEC strains are usually 
treated with antimicrobial drugs and uncomplicated UTIs with nitrofurantoin or TMP/SXT; 
complicated UTIs may also be treated with fluoroquinolones [34–37]. Infections with ESBL or 
CRE strains severely limit treatment options. For ESBL strains, carbapenems may still be an 
option or newer β-lactam/β-lactamase inhibitor drug combinations; for CRE strains, gentami-
cin, amikacin, colistin, tigecycline, and fosfomycin may be options. Unfortunately, some ESBL 
and CRE strains may be resistant to even some of these drugs [38–40].
At the beginning of antimicrobial drug resistance, physicians did not realize how the various 
drugs affected the bacteria. In addition, in an effort to begin antimicrobial therapy as quickly 
as possible, physicians often ordered a broad-spectrum drug before knowing the causative 
agent of the infection. These issues (among others) have led to a large amount of resistance 
to β-lactam drugs, especially among the gram-negative bacteria. Bacteria that produced 
β-lactamases (enzymes that inactivate β-lactam drugs) were identified as early as the 1940s 
(around the same time as penicillin was discovered), and the number of different β-lactamases 
produced has increased over the years to around 1000 [2–4, 41].
The issue of resistance is not just with the β-lactam drugs. Over the 70 plus years that antimi-
crobial drugs have been in existence, resistance mechanisms have been seen for most of these 
drugs. It does not seem to take the bacteria very long from initial use of a drug to development 
of resistance to that drug. Important resistant milestones include resistance to aminoglyco-
sides and tetracycline in the 1960s, vancomycin in the 1980s, fluoroquinolones in the 1990s, 
and linezolid in the 2000s [42]. In addition, some of the bacteria have become resistant to 
multiple antimicrobial agents from many of the drug classes. These multidrug-resistant bac-
teria, such as methicillin-resistant Staphylococcus aureus (MRSA), are currently a major cause 
of morbidity and mortality [43].
Similar to the threat of MRSA, members of the gram-negative Enterobacteriaceae, in particu-
lar E. coli and Klebsiella pneumoniae, include strains that are ESBLs and CREs. These organisms 
can be resistant to most commonly used antimicrobials, which makes the infections they cause 
extremely difficult to treat, leading to increased morbidity and mortality (and healthcare costs) 
[44, 45].
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4. Antimicrobial resistance mechanisms
There are four general antimicrobial resistance mechanisms that bacteria use. These are lim-
iting uptake of the drug, modifying the target of the drug, inactivating the drug, and active 
efflux of the drug. These mechanisms may be located on the bacterial chromosome and occur 
naturally in all members of a species (intrinsic) or come from other bacteria, usually via a plas-
mid (acquired). Intrinsic resistance genes may be expressed constitutively (usually at a low 
level) or be induced by the presence of antimicrobial drugs. Gram-negative bacteria widely 
use all four of these mechanisms and are very capable of horizontal transfer of resistance ele-
ments. Table 2 shows which resistance mechanisms and genes are associated with resistance 
to various antimicrobial drugs [43, 46, 47].
4.1. Limiting drug uptake
Gram-negative bacteria have an advantage in combating drugs because of the structure and 
functions of the LPS cell wall, which provides a natural barrier to certain molecules. The 
LPS is generally hydrophobic which limits access to small hydrophilic drugs, such as the 
β-lactams. These hydrophilic drugs gain access by traveling through the OMPs. The main 
 
Antimicrobial agents Mechanisms of resistance Genetic basis
β-lactams
Penicillins
Cephalosporins
Monobactams
Carbapenems
β-lactamases—inactivate drugs
Active efflux
ampC
bla genes—plasmid
(TEM, SHV, CTX-M, NDM)
acrAB(tolC), acrAD(tolC)
Aminoglycosides
Amikacin
Gentamicin
Tobramycin
Aminoglycoside modifying enzymes
Modify target—16S rRNA
Active efflux
aac, ant, aph—plasmid
amrA, rmtB
mdtEF(tolC)
Tetracyclines
Tetracycline
Limiting uptake
Active efflux
ompF
acrAB(tolC)
tetA, tetB—plasmid
Chloramphenicol Limiting uptake
Active efflux
ompF
acrAB(tolC)
Fluoroquinolones
Ciprofloxacin
Norfloxacin
Limiting uptake
Modified target—gyrase
Modified target—topoisomerase IV
Active efflux
ompF
gyrA
parC
acrAB(tolC), acrEF(tolC), 
mdtABC(tolC)
Metabolic pathway inhibitors
Trimethoprim/Sulfamethoxazole
Target enzyme modification TMP—dhfr
SXT—dhps
Table 2. Common antimicrobial resistance genes and mechanisms in Escherichia coli.
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OMPs in E. coli are OmpF and OmpC. In addition to the β-lactams, other drugs that may use 
the porin channels are chloramphenicol, fluoroquinolones, and tetracycline. Hydrophobic 
drugs such as the aminoglycosides and the macrolides gain access by permeating through the 
LPS layer. There are two main mechanisms that are used to limit access to drugs via porins: 
a decrease in the number of porins or a change in charge, within the porin channel, which 
reduces its function or binding properties. In E. coli porin production may be reduced dra-
matically or even stopped, or a different porin may be produced instead [48, 49].
4.2. Modifying drug target
Gram-negative bacteria make use of the modifying of drug targets against several of the 
antimicrobial groups including β-lactams, aminoglycosides, fluoroquinolones, and the com-
bination drug TMP/SXT. Even though not as widely used as in gram-positive bacteria, the 
gram-negative bacteria are able to produce penicillin-binding proteins (PBPs) that are resis-
tant to some β-lactam drugs. PBPs are actually peptidases that are involved in the making of 
the peptidoglycan cell wall. Penicillin drugs that are able to bind to PBPs inhibit the assembly 
process. There are several different native PBPs produced by E. coli, some of which have 
reduced binding affinity for some of the β-lactam drugs. No acquired modified form of PBP 
has been shown to be significant in β-lactam resistance in E. coli [50, 51].
The aminoglycoside drugs inhibit protein synthesis by binding to the bacterial 30S ribosomal 
subunit at the A-site of the 16S rRNA. Bacteria are able to modify the ribosomal subunit via 
acquisition of plasmids carrying 16S rRNA methyltransferases. The methyltransferases are 
able to modify the structure of the 16S rRNA, which decreases the ability of the drug to bind 
to it. Several of these methyltransferases have been identified and characterized. The genes 
involved include armA (for aminoglycoside resistance methylase) and several rmt (for ribo-
somal methyltransferase) genes, with rmtB being the most common. The bacteria quite often 
possess several of these genes simultaneously. These genes most often confer clinically sig-
nificant resistance to amikacin, gentamicin, and tobramycin, among other aminoglycosides 
[52–56].
The fluoroquinolone drugs interfere with nucleic acid synthesis during DNA replication by 
inhibiting either DNA gyrase or topoisomerase IV. Resistance to these drugs occurs commonly 
from mutations in either the chromosomally encoded GyrA subunit of gyrase (gyrA gene) or the 
ParC subunit of topoisomerase IV (parC gene). These mutations decrease the binding ability of 
the drugs, most commonly ciprofloxacin and norfloxacin. There is also some evidence that low-
level resistance may be acquired via plasmids carrying quinolone resistance (qnr) genes [56–58].
The combination drug TMP/SXT is currently a common choice for treatment of UTIs. Both 
of these drugs target enzymes in the bacterial folate biosynthesis pathway via competitive 
inhibition. Trimethoprim is an analog of the natural substrate of the dihydrofolate reductase 
(DHFR) enzyme, and SXT is an analog of p-amino-benzoic acid, the natural substrate of the 
dihydropteroate synthase (DHPS) enzyme. This competitive binding blocks the binding of 
the natural substrate and stops the pathway at that point. Since TMP and SXT affect two dif-
ferent enzymes on the same pathway, the combination drug makes an effective treatment. 
Chromosomal mutations (often single point mutations) in the dhfr or dhps genes are com-
monly the cause of resistance to these drugs [59, 60].
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4.3. Inactivating the drug
Drug inactivation is accomplished in one of two ways: by actual degradation of the drug or 
by transfer of a chemical group to the drug. Gram-negative bacteria use drug inactivation 
against β-lactams and aminoglycosides. The β-lactam drugs are universally inactivated by 
β-lactamase enzymes, which degrade the drugs, and E. coli produces several of these. The 
aminoglycoside drugs are inactivated fairly universally by enzymes that transfer one of three 
small chemical groups to the drug. These enzymes include the acetyltransferases (AACs, aac 
genes), nucleotidyltransferases (ANTs, ant genes), and the phosphotransferases (APHs, aph 
genes) [43, 49, 61].
4.3.1. β-lactamases
The β-lactam drugs all share a specific core structure, which consists of a four-sided β-lactam 
ring. The β-lactamases (also originally called penicillinases and cephalosporinases) are capa-
ble of inactivating β-lactam drugs via hydrolyzation of a specific site in the β-lactam ring struc-
ture causing the ring to open. The drugs are then not able to bind to their target proteins, the 
PBPs. Within the large number of β-lactamases which have been identified, there are enzymes 
which can inactivate any of the current β-lactam drugs. The production of β-lactamases is the 
most common resistance mechanism used by gram-negative bacteria against β-lactam drugs 
[46, 62].
The β-lactamase enzymes can be classified based on their primary structure or functional 
characteristics. Structurally they are placed into four main categories (A, B, C, or D). There are 
three functional groupings: the cephalosporinases, the serine β-lactamases, and the metallo-β-
lactamases. These enzymes are also commonly referred to by their enzyme family, for exam-
ple, the TEM (named after the first patient) family, the sulphydryl variable (SHV) family, and 
the CTX (preferentially hydrolyze cefotaxime) family [56, 63].
The first β-lactamase to be characterized was from E. coli and is chromosomally encoded by 
the ampC gene (so named for ampicillin resistance). This gene is constitutively expressed at a 
low level, but mutations may result in overexpression of the gene. The AmpC β-lactamases 
are most effective against the penicillins and some first-generation cephalosporins. There 
are also many plasmid-borne β-lactamases, which carry a variety of bla genes (β-lactamase 
genes). Because these β-lactamases confer resistance to later generation cephalosporins, they 
were designated as ESBLs and include the TEM, SHV, and CTX-M enzyme families. The most 
commonly seen of these in E. coli are the CTX-Ms. The ESBLs may also be resistant to multiple 
drug classes but are generally sensitive to β-lactamase inhibitors. The β-lactamase inhibitors 
are structurally similar to β-lactamases and have weak antimicrobial ability alone but work 
synergistically in combination with a β-lactam drug [56, 64–67].
Recently, there has been emergence of β-lactamases that are active against the carbapenems 
(carbapenemases), found primarily in the Enterobacteriaceae. Bacterial strains that carry these 
are known as CRE strains. The carbapenemases are all metallo-β-lactamases (MBLs), and the 
most widely distributed are the IMP-1 (for imipenem resistance) and VIM-1 (Verona integron-
encoded MBL) types. A new MBL has recently been identified, mainly in strains of E. coli. It 
has been designated as New Delhi MBL (NDM-1). The CRE strains are usually resistance to 
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all the β-lactam drugs and are not inactivated by the standard β-lactam/β-lactamase inhibi-
tor combination drugs. There is a newer β-lactamase inhibitor, avibactam, which has been 
approved for use with ceftazidime against gram-negative bacteria. In addition, avibactam is 
being tested for use with aztreonam against CREs [62, 66–68].
4.4. Drug efflux
Bacteria possess methods for disposal of toxic substances to the outside of the cell. The most 
commonly used mechanism is the efflux pump. Most bacteria have chromosomally encoded 
efflux pump genes. Some of these pumps are expressed constitutively, and expression of 
others is induced by various environmental stimuli. Many of these pumps are capable 
of transporting a variety of substances and are also described as multidrug (MDR) efflux 
pumps. There are five efflux pump family groups: the ATP-binding cassette (ABC) family, 
the multidrug and toxic compound extrusion (MATE) family, the major facilitator super-
family (MFS), the small multidrug resistance (SMR) family, and the resistance-nodulation-
cell division (RND) family. The RND pumps are generally found only in gram-negative 
bacteria as these pumps are multicomponent pumps that function in association with an 
OMP [69–72].
There is only one ABC efflux pump in E. coli that is known to contribute to antimicrobial 
resistance. That is the MacAB transporter that confers resistance to some macrolides [73]. 
There is also only one MATE efflux pump found in E. coli, the NorE pump which is able to 
transport fluoroquinolones. It is still in question if the NorE pump has a clinically significant 
impact on antimicrobial resistance [74, 75]. There are five known MFS efflux pumps found 
in E. coli. These are capable of transporting macrolides (MefB and MdfA pumps), fluoro-
quinolones (QepA2, EmrAB-TolC, and MdfA pumps), tetracycline (EmrAB-TolC and MdfA 
pumps), trimethoprim (Fsr pump), and chloramphenicol (MdfA pump). In addition, there 
are several MFS pumps that may be acquired by E. coli (e.g., via plasmids) that are specific 
for tetracyclines, with tetA and tetB being the most common [76, 77]. There are no clinically 
significant SMR efflux pumps found in E. coli [78].
The RND efflux pumps are the most clinically significant pumps found in gram-negative bac-
teria. These pumps consist of three components (tripartite): an inner membrane transporter, 
an outer membrane porin, and a periplasmic accessory protein that functions to connect the 
other two components. In E. coli, the OMP that is associated with all of the antimicrobial 
efflux pumps is TolC. There are five known RND pumps in E. coli: AcrAB-TolC, AcrAD-TolC, 
AcrEF-TolC, MdtABC-TolC, and MdtEF-TolC. AcrAD-TolC has been shown to efflux amino-
glycosides and β-lactams. AcrEF-TolC has been shown to efflux quinolones and tigecycline. 
MdtABE-TolC has been shown to efflux quinolones. MdtEF-TolC has been shown to efflux 
erythromycin. The level of expression of these four pumps is relatively low, and if operating 
alone, the amount of antimicrobials effluxed would probably not be significant. Because E. coli 
has five efflux systems plus multiple other types of antimicrobial resistance mechanisms in 
play, these pumps undoubtedly help out. The other RND efflux pump in E. coli, AcrAB-TolC, 
is the most clinically significant and accounts for major antimicrobial efflux. This pump has 
been shown to efflux β-lactams, fluoroquinolones, tetracyclines, chloramphenicol, and lincos-
amides [72, 79, 80].
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5. Conclusion
For many strains of pathogenic E. coli, the most common course of therapy is supportive and 
does not require the use of antimicrobial drugs, or in the case of EHEC, antimicrobial therapy 
is not recommended. For severe intestinal infections and UTIs, antimicrobial therapy may be 
necessary. Unfortunately with the issue of ever increasing antimicrobial resistance, the anti-
microbial options are becoming fewer. With the emergence of ESBL and CRE E. coli strains, 
the options have gotten extremely limited, and antimicrobial development has not been able 
to keep up with the demand. Hopefully the newer carbapenem/β-lactamase inhibitor com-
bination drugs and other drugs being developed under the tetracycline and aminoglycoside 
drug classes will prove to be equal to the task or at least keep the bacteria under control until 
better options become available.
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